دورية أكاديمية
A natural killer T cell nanoagonist-initiated immune cascade for hepatocellular carcinoma synergistic immunotherapy.
| العنوان: | A natural killer T cell nanoagonist-initiated immune cascade for hepatocellular carcinoma synergistic immunotherapy. |
|---|---|
| المؤلفون: | Luo T; School of Medicine, Nankai University, Tianjin, 300071, China. liangping301@hotmail.com.; Department of Interventional Ultrasound, Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, 100853, China. jiemi301@163.com.; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, 100190, China. Liangxj@nanoctr.cn., Tan X; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, 100190, China. Liangxj@nanoctr.cn., Qing G; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, 100190, China. Liangxj@nanoctr.cn., Yu J; Department of Interventional Ultrasound, Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, 100853, China. jiemi301@163.com., Liang XJ; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, 100190, China. Liangxj@nanoctr.cn.; University of Chinese Academy of Sciences, Beijing 100049, China., Liang P; School of Medicine, Nankai University, Tianjin, 300071, China. liangping301@hotmail.com.; Department of Interventional Ultrasound, Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, 100853, China. jiemi301@163.com. |
| المصدر: | Nanoscale [Nanoscale] 2024 Jun 13; Vol. 16 (23), pp. 11126-11137. Date of Electronic Publication: 2024 Jun 13. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: RSC Pub Country of Publication: England NLM ID: 101525249 Publication Model: Electronic Cited Medium: Internet ISSN: 2040-3372 (Electronic) Linking ISSN: 20403364 NLM ISO Abbreviation: Nanoscale Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Cambridge, UK : RSC Pub. |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/immunology , Carcinoma, Hepatocellular*/drug therapy , Liver Neoplasms*/therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/immunology , Liver Neoplasms*/drug therapy , Natural Killer T-Cells*/immunology , Natural Killer T-Cells*/drug effects , Doxorubicin*/chemistry , Doxorubicin*/pharmacology , Doxorubicin*/therapeutic use , Immunotherapy* , Tumor Microenvironment*/drug effects , Tumor Microenvironment*/immunology , Galactosylceramides*/chemistry , Galactosylceramides*/pharmacology , Hyaluronic Acid*/chemistry , Hyaluronic Acid*/pharmacology, Animals ; Mice ; Humans ; Cell Line, Tumor ; Metal-Organic Frameworks/chemistry ; Metal-Organic Frameworks/pharmacology ; Nanoparticles/chemistry ; Nanoparticles/therapeutic use |
| مستخلص: | Natural killer T (NKT) cell-mediated immunotherapy shows great promise in hepatocellular carcinoma featuring an inherent immunosuppressive microenvironment. However, targeted delivery of NKT cell agonists remains challenging. Here, we developed a hyaluronic acid (HA) modified metal organic framework (zeolitic imidazolate framework-8, ZIF-8) to encapsulate α-galactosylceramide (α-Galcer), a classic NKT cell agonist, and doxorubicin (DOX) for eliminating liver cancer, denoted as α-Galcer/DOX@ZIF-8@HA. In the tumor microenvironment (TME), these pH-responsive nano-frameworks can gradually collapse to release α-Galcer for activating NKT cells and further boosting other immune cells in order to initiate an antitumor immune cascade. Along with DOX, the released α-Galcer enabled efficient NKT cell activation in TME for synergistic immunotherapy and tumor elimination, leading to evident tumor suppression and prolonged animal survival in both subcutaneous and orthotopic liver tumor models. Manipulating NKT cell agonists into functional nano-frameworks in TME may be matched with other advanced managements applied in a wider range of cancer therapies. |
| المشرفين على المادة: | 80168379AG (Doxorubicin) 0 (Galactosylceramides) 0 (alpha-galactosylceramide) 9004-61-9 (Hyaluronic Acid) 0 (Metal-Organic Frameworks) |
| تواريخ الأحداث: | Date Created: 20240524 Date Completed: 20240613 Latest Revision: 20240613 |
| رمز التحديث: | 20240613 |
| DOI: | 10.1039/d4nr00847b |
| PMID: | 38787697 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2040-3372 |
|---|---|
| DOI: | 10.1039/d4nr00847b |